Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Challenges with the 4th Universal Definition of Myocardial Infarction - the unsolved issue of Type 2 and the arbitrariness of Type 4 and 5
Vascul Pharmacol. 2024 Mar 10:107365. doi: 10.1016/j.vph.2024.107365. Online ahead of print.NO ABSTRACTPMID:38471618 | DOI:10.1016/j.vph.2024.107365 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Authors: Pedro Lopez-Ayala Raffaele De Caterina Christian Mueller Source Type: research
Challenges with the 4th Universal Definition of Myocardial Infarction - the unsolved issue of Type 2 and the arbitrariness of Type 4 and 5
Vascul Pharmacol. 2024 Mar 10:107365. doi: 10.1016/j.vph.2024.107365. Online ahead of print.NO ABSTRACTPMID:38471618 | DOI:10.1016/j.vph.2024.107365 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Authors: Pedro Lopez-Ayala Raffaele De Caterina Christian Mueller Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Mar 1;155:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Sou...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Feb 29:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Source...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Feb 29:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Source...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Feb 29:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Source...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Feb 29:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Source...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Feb 29:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Source...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment
Vascul Pharmacol. 2024 Feb 29:107285. doi: 10.1016/j.vph.2024.107285. Online ahead of print.ABSTRACTAngina contributes to significant morbidity worldwide. The evaluation of angina is variable and complicated by multiple factors. The diagnosis is often focussed on epicardial disease despite the knowledge that chest pain can be due to cardiac, non-cardiac, macro, and microvascular causes. Standardised diagnostic pathways and novel approaches to angina assessment may offer the opportunity to improve our understanding of angina and apply a personalised approach to treatment.PMID:38431201 | DOI:10.1016/j.vph.2024.107285 (Source...
Source: Vascular Pharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Rasha K Al-Lamee Source Type: research
12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection
Vascul Pharmacol. 2024 Feb 28:107288. doi: 10.1016/j.vph.2024.107288. Online ahead of print.ABSTRACTCombination antiretroviral therapy (cART) has markedly increased life expectancy in people with HIV (PWH) but has also resulted in an increased prevalence of cardiometabolic disorders, whose etiopathology remains ill-defined. Notably, the respective contribution of cART and HIV-derived proteins to obesity and vascular alterations remain poorly understood. Therefore, we investigated the individual and combined effects of HIV-proteins and of the integrase strand transfer inhibitor Dolutegravir (DTG) on body composition and vas...
Source: Vascular Pharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Taylor C Kress Priscilla Ajala Coleton R Jordan James Mintz Rodger MacArthur Simone Kennard Galina Antonova Eric J Belin de Chantem èle Source Type: research
12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection
Vascul Pharmacol. 2024 Feb 28:107288. doi: 10.1016/j.vph.2024.107288. Online ahead of print.ABSTRACTCombination antiretroviral therapy (cART) has markedly increased life expectancy in people with HIV (PWH) but has also resulted in an increased prevalence of cardiometabolic disorders, whose etiopathology remains ill-defined. Notably, the respective contribution of cART and HIV-derived proteins to obesity and vascular alterations remain poorly understood. Therefore, we investigated the individual and combined effects of HIV-proteins and of the integrase strand transfer inhibitor Dolutegravir (DTG) on body composition and vas...
Source: Vascular Pharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Taylor C Kress Priscilla Ajala Coleton R Jordan James Mintz Rodger MacArthur Simone Kennard Galina Antonova Eric J Belin de Chantem èle Source Type: research
A critical appreciation of pathway analysis in atherosclerotic disease. Cellular phenotypic plasticity as an illustrative example
Vascul Pharmacol. 2024 Feb 24;154:107286. doi: 10.1016/j.vph.2024.107286. Online ahead of print.ABSTRACTThe rapid advancements in genome-scale (omics) techniques has created significant opportunities to investigate complex disease mechanisms in tissues and cells. Nevertheless, interpreting -omics data can be challenging, and pathway enrichment analysis is a frequently used method to identify candidate molecular pathways that drive gene expression changes. With a growing number of -omics studies dedicated to atherosclerosis, there has been a significant increase in studies and hypotheses relying on enrichment analysis. This...
Source: Vascular Pharmacology - February 26, 2024 Category: Drugs & Pharmacology Authors: M Wesseling E Diez-Benavente M Mokry H M den Ruijter G Pasterkamp Source Type: research
